Novo Nordisk's investigational drug CagriSema did not meet its primary endpoint in a Phase III clinical trial evaluating its efficacy in treating obesity. The trial aimed to demonstrate superior weight loss with CagriSema compared to semaglutide alone, but the combination therapy failed to achieve statistical significance on this measure.
The Phase III study involved adult participants with a body mass index (BMI) of 27 kg/m² or greater, indicating overweight or obesity. Participants were administered CagriSema, which combines cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. The trial's primary endpoint was the percentage change in body weight from baseline to week 52.
While CagriSema did not meet the primary endpoint, Novo Nordisk indicated that they are continuing to analyze the data to fully understand the results. The company remains dedicated to advancing obesity treatment and is actively pursuing other therapeutic avenues. The failure to meet the primary endpoint in this trial represents a setback for Novo Nordisk's obesity pipeline.
Following the announcement of the trial results, Novo Nordisk's stock experienced a significant decline, reflecting investor concern over the future prospects of CagriSema and its potential impact on the company's obesity franchise. Further details regarding the trial's secondary endpoints and safety profile have not yet been released.
